Binding antibodies (BAbs) and neutralizing antibodies (NAbs) develop following the use of interferon beta (IFNβ) in patients with relapsing-remitting multiple sclerosis (RRMS). The appearance of anti-IFNβ antibodies has been associated with reduction of the therapeutic efficacy of IFNβ therapy; however, while BAbs and NAbs arise from exposure to IFNβ, they have different characteristics and different impacts on clinical outcomes. Not all patients develop BAbs and NAbs, and patients who do may revert to seronegative status for each of these antibodies, even with continued IFNβ treatment. This review examines the potential clinical and biological effect of BAbs and NAbs on therapeutic efficacy in the treatment of RRMS. Multiple Sclerosis 2007; 13: S36—S43. http://msj.sagepub.com
Bellomi F., Scagnolari C., Tomassini V., Gasperini C., Paolillo A., Pozzilli C. et al. Fate of neutralilzing and binding antidotes to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci2003; 215: 3—8.
2.
Deisenhammer F., Schellekens H., Bertolotto A.Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neuro2004; 215(Suppl 2): 1131—39.
3.
Runkel L., De DC, Karpusas M., Baker D., Li Z., Zafari M. et al. Mapping of IFN-beta epitopes important for receptor binding and biologic activation:comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res2001; 21: 931—41.
4.
Chadha K., Weinstock-Guttman B., Zivadinov R., Bhasi K., Muhitch J., Feichter J. et al. Interferon inhibitory activity in patients with multiple sclerosis. Archives ofNeurology2006; 63: 1579—84.
5.
Francis GS, Rice GP, Alsop JCInterferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology2005; 65: 48—55.
6.
Pachner AR, Dail D., Pak E., Narayan K.The importance of measuring IFNbeta bioactivity: Monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol2005; 166: 180—88.
Rice GP, Paszner B., Oger J., Lesaux J., Paty D., Ebers G.The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology1999; 52: 1277—79.
9.
Gibbs E., MacDonnell G., Deisenhammer F., Oger J.Binding antibodies to Interferon Beta during Treatment of MS are biologically and clinically relevant. Neurology2002; 58: A72.
10.
Gibbs E., Tremlett H., Smyth P., Aziz T., Oger J.The significant influence of binding antibodies on outcome measures I IFN Beta-treated MS patients. Neurology2003; 60: A56.
11.
Perini P., Calabrese M., Biasi G., Gallo P.The clinical impact of interferon beta antibodies in relapsing-remitting MS . J Neurol2004; 251: 305—309.
12.
Sorensen PS , Koch-Henriksen N., Ross C., Clemmesen KM, Bendtzen K.Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology2005; 65: 33—39.
13.
Cook SD, Quinless JR, Jotkowitz A., Beaton P.Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology2001; 57: 1080—84.
14.
Vallittu AM , Halminen M., Peltoniemi J., Ilonen J., Julkunen I., Salmi A. et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology2002; 58: 1786—90.
15.
Smythe PS, Gibbs E., Tremlett H., Pachner A., Oger J.MxA induction can be regarded after loss of neurtralizing antibodies with continued interferon-β treatment. Multiple Sclerosis2004; 10: S252, 618.
16.
Bertelotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E. et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology2003; 60: 634—39.
17.
McKay F., Schibeci S., Heard R., Stewart G., Booth D.Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients; a comparison of three methods in a large Australian cohort . Journal of Imm Methods2006; 310: 20—29.
18.
Shapiro AM, Jack CS, Lapierre Y., Arbour N., Bar-Or A., Antel JPPotential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Archives of Neuro.2006; 63: 1296—99.
19.
Sorensen PS, Tscherning T., Mathiesen HK, Langkilde AR, Ross C., Ravnborg M. et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology2006; 67: 1681—83.
20.
Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Di Sapio A. et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol2005; 158: 195—203.
21.
Kappos L., Clanet M., Sandberg-Wollheim M., Radue EW, Hartung HP, Hohlfeld R. et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology2005; 65: 40—47.
22.
Sorensen PS , Ross C., Clemmesen KM, Bendtzen K., Frederiksen JL, Jensen K. et al. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet2003; 362: 1184—91.
23.
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiples Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group.Neurology1996; 47: 889—94.
24.
Giovannoni G., Goodman A.Neutralizing anti-IFNbeta antibodies:how much more evidence do we need to use them in practice?Neurology2005; 65: 6—8.
25.
Vartanian T. , Solberg SP, Rice G.Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol2004; 251(Suppl 2): 1125—30.
